泽璟制药：注射用ZG006治疗晚期神经内分泌癌纳入突破性治疗品种公示名单

Core Viewpoint - Zai Lab's investigational product ZG006 has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) for the treatment of DLL3-positive advanced neuroendocrine carcinoma patients who have relapsed or progressed after at least one platinum-based therapy [1] Group 1 - ZG006 is indicated for monotherapy in patients with DLL3-positive advanced neuroendocrine carcinoma [1] - The announcement was made on November 24, 2023, and the public notice period is from November 24, 2025, to December 1, 2025 [1] - There is a risk of objections during the public notice period [1]